Do analysts recommend KROS or APLM?

Keros Therapeutics currently has a consensus price target of $20.50, suggesting a potential upside of 84.52%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keros Therapeutics 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, KROS or APLM?

Keros Therapeutics has higher revenue and earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Keros Therapeutics $244.06M 0.90 $87.01M -$3.70 N/A Apollomics $8.50M 7.25 -$10.94M N/A N/A

Do analysts prefer APLM or PEPG?

PepGen has a consensus target price of $11.50, suggesting a potential upside of 261.64%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has better earnings & valuation, APLM or PEPG?

Apollomics has higher revenue and earnings than PepGen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.25 -$10.94M N/A N/A PepGen N/A N/A -$89.65M -$1.31 N/A

Is APLM or PEPG more profitable?

Apollomics' return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A PepGen N/A -51.01% -43.49%

Do analysts prefer APLM or ORMP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation and earnings, APLM or ORMP?

Oramed Pharmaceuticals has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.25 -$10.94M N/A N/A Oramed Pharmaceuticals $2M 102.54 $64.05M $4.12 1.20

Is APLM or ORMP more profitable?

Apollomics' return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Oramed Pharmaceuticals N/A -5.17% -4.54%

Do analysts rate APLM or ORGO?

Organogenesis has a consensus target price of $4.33, suggesting a potential upside of 164.23%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts plainly believe Organogenesis is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Organogenesis 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher earnings & valuation, APLM or ORGO?

Organogenesis has higher revenue and earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.25 -$10.94M N/A N/A Organogenesis $564.17M 0.37 $37.03M -$0.86 N/A

Do analysts recommend APLM or ABOS?

Acumen Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 158.90%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable earnings & valuation, APLM or ABOS?

Apollomics has higher revenue and earnings than Acumen Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 7.25 -$10.94M N/A N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.63 N/A

Is APLM or ABOS more profitable?

Apollomics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Acumen Pharmaceuticals N/A -136.27% -81.64%

Apollomics (APLM) Competitors

$28.01 +0.66 (+2.41%)

As of 03:15 PM Eastern

Compare

APLM vs. KROS, PEPG, ORMP, ORGO, and ABOS

Should you buy Apollomics stock or one of its competitors? Apollomics's main competitors and comparable companies include Keros Therapeutics (KROS), PepGen (PEPG), Oramed Pharmaceuticals (ORMP), Organogenesis (ORGO), and Acumen Pharmaceuticals (ABOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Apollomics compare to Keros Therapeutics?

Keros Therapeutics (NASDAQ:KROS) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

71.6% of Keros Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 12.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Keros Therapeutics has higher revenue and earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keros Therapeutics	$244.06M	0.90	$87.01M	-$3.70	N/A
Apollomics	$8.50M	7.25	-$10.94M	N/A	N/A

Keros Therapeutics currently has a consensus price target of $20.50, suggesting a potential upside of 84.52%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Keros Therapeutics has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market.

In the previous week, Keros Therapeutics had 6 more articles in the media than Apollomics. MarketBeat recorded 6 mentions for Keros Therapeutics and 0 mentions for Apollomics. Keros Therapeutics' average media sentiment score of 1.61 beat Apollomics' score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Keros Therapeutics	Very Positive
Apollomics	Neutral

Apollomics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Apollomics' return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keros Therapeutics	-256.60%	-21.40%	-19.79%
Apollomics	N/A	N/A	N/A

Summary

Keros Therapeutics beats Apollomics on 9 of the 14 factors compared between the two stocks.

How does Apollomics compare to PepGen?

Apollomics (NASDAQ:APLM) and PepGen (NASDAQ:PEPG) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Apollomics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, PepGen has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market.

Apollomics has higher revenue and earnings than PepGen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.25	-$10.94M	N/A	N/A
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A

19.1% of Apollomics shares are held by institutional investors. Comparatively, 58.0% of PepGen shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Apollomics' average media sentiment score of 0.00 equaled PepGen'saverage media sentiment score.

Company	Overall Sentiment
Apollomics	Neutral
PepGen	Neutral

Apollomics' return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
PepGen	N/A	-51.01%	-43.49%

PepGen has a consensus target price of $11.50, suggesting a potential upside of 261.64%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

PepGen beats Apollomics on 6 of the 10 factors compared between the two stocks.

How does Apollomics compare to Oramed Pharmaceuticals?

Apollomics (NASDAQ:APLM) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Apollomics' return on equity of 0.00% beat Oramed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

Apollomics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Oramed Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Oramed Pharmaceuticals has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.25	-$10.94M	N/A	N/A
Oramed Pharmaceuticals	$2M	102.54	$64.05M	$4.12	1.20

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Oramed Pharmaceuticals had 4 more articles in the media than Apollomics. MarketBeat recorded 4 mentions for Oramed Pharmaceuticals and 0 mentions for Apollomics. Oramed Pharmaceuticals' average media sentiment score of 0.01 beat Apollomics' score of 0.00 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Apollomics	Neutral
Oramed Pharmaceuticals	Neutral

19.1% of Apollomics shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 20.8% of Oramed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Oramed Pharmaceuticals beats Apollomics on 6 of the 11 factors compared between the two stocks.

How does Apollomics compare to Organogenesis?

Apollomics (NASDAQ:APLM) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Organogenesis has a consensus target price of $4.33, suggesting a potential upside of 164.23%. Given Organogenesis' stronger consensus rating and higher possible upside, analysts plainly believe Organogenesis is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Apollomics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Organogenesis has higher revenue and earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.25	-$10.94M	N/A	N/A
Organogenesis	$564.17M	0.37	$37.03M	-$0.86	N/A

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Apollomics' average media sentiment score of 0.00 beat Organogenesis' score of -0.48 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Neutral
Organogenesis	Neutral

Apollomics has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Apollomics' return on equity of 0.00% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Organogenesis	-19.94%	-23.89%	-11.13%

Summary

Apollomics and Organogenesis tied by winning 6 of the 12 factors compared between the two stocks.

How does Apollomics compare to Acumen Pharmaceuticals?

Apollomics (NASDAQ:APLM) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Acumen Pharmaceuticals had 1 more articles in the media than Apollomics. MarketBeat recorded 1 mentions for Acumen Pharmaceuticals and 0 mentions for Apollomics. Apollomics' average media sentiment score of 0.00 equaled Acumen Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Apollomics	Neutral
Acumen Pharmaceuticals	Neutral

Apollomics has higher revenue and earnings than Acumen Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	7.25	-$10.94M	N/A	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A

Apollomics has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.37, meaning that its share price is 63% less volatile than the broader market.

Apollomics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%

Acumen Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 158.90%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Acumen Pharmaceuticals beats Apollomics on 6 of the 11 factors compared between the two stocks.

Get Apollomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLM vs. The Competition

Export

Metric	Apollomics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$60.05M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	N/A	12.66	273.28	25.38
Price / Sales	7.25	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-9.69	16.29	12.89	6.14
Net Income	-$10.94M	-$22.72M	$3.47B	$349.01M
7 Day Performance	6.50%	-1.37%	-0.33%	-1.47%
1 Month Performance	62.90%	11.07%	6.51%	2.47%
1 Year Performance	569.30%	53.71%	25.19%	15.84%

Apollomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLM Apollomics	1.5897 of 5 stars	$28.01 +2.4%	N/A	+540.1%	$60.05M	$8.50M	N/A	45	Analyst Downgrade
KROS Keros Therapeutics	3.6489 of 5 stars	$11.35 -2.8%	$20.50 +80.6%	-28.6%	$225.07M	$244.06M	N/A	100
PEPG PepGen	1.7725 of 5 stars	$3.20 -6.6%	$11.50 +259.9%	+165.0%	$220.59M	N/A	N/A	30	Positive News
ORMP Oramed Pharmaceuticals	1.9163 of 5 stars	$5.29 +1.4%	N/A	+135.8%	$220.02M	$2M	1.28	10	News Coverage Analyst Revision
ORGO Organogenesis	1.385 of 5 stars	$1.71 -2.0%	$4.33 +154.2%	-65.9%	$219.40M	$564.17M	N/A	950

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLM) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apollomics (APLM) Competitors

APLM vs. KROS, PEPG, ORMP, ORGO, and ABOS

How does Apollomics compare to Keros Therapeutics?

Summary

How does Apollomics compare to PepGen?

Summary

How does Apollomics compare to Oramed Pharmaceuticals?

Summary

How does Apollomics compare to Organogenesis?

Summary

How does Apollomics compare to Acumen Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apollomics (APLM) Competitors

APLM vs. KROS, PEPG, ORMP, ORGO, and ABOS

How does Apollomics compare to Keros Therapeutics?

Do institutionals and insiders hold more shares of KROS or APLM?

Which has higher earnings & valuation, KROS or APLM?

Do analysts recommend KROS or APLM?

Which has more risk and volatility, KROS or APLM?

Does the media favor KROS or APLM?

Is KROS or APLM more profitable?

Summary

How does Apollomics compare to PepGen?

Which has more risk & volatility, APLM or PEPG?

Which has better earnings & valuation, APLM or PEPG?

Do institutionals & insiders hold more shares of APLM or PEPG?

Does the media refer more to APLM or PEPG?

Is APLM or PEPG more profitable?

Do analysts prefer APLM or PEPG?

Summary

How does Apollomics compare to Oramed Pharmaceuticals?

Is APLM or ORMP more profitable?

Which has more volatility and risk, APLM or ORMP?

Which has better valuation and earnings, APLM or ORMP?

Do analysts prefer APLM or ORMP?

Does the media favor APLM or ORMP?

Do insiders and institutionals hold more shares of APLM or ORMP?

Summary

How does Apollomics compare to Organogenesis?

Do analysts rate APLM or ORGO?

Which has more volatility & risk, APLM or ORGO?

Which has higher earnings & valuation, APLM or ORGO?

Do insiders and institutionals have more ownership in APLM or ORGO?

Does the media refer more to APLM or ORGO?

Is APLM or ORGO more profitable?

Summary

How does Apollomics compare to Acumen Pharmaceuticals?

Do institutionals & insiders hold more shares of APLM or ABOS?

Does the media favor APLM or ABOS?

Which has preferable earnings & valuation, APLM or ABOS?

Which has more volatility & risk, APLM or ABOS?

Is APLM or ABOS more profitable?

Do analysts recommend APLM or ABOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM vs. The Competition

Apollomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools